Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

CPEX Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company, incorporated in the state of Delaware, with principal executive offices located at 2 Holland Way, Exeter, New Hampshire. We are in the business of research and development of pharmaceutical products utilizing our validated drug delivery platform technology. We have U.S. and international patents and other proprietary rights to technology that facilitates the absorption of drugs. Our platform drug delivery technology enhances permeation and absorption of pharmaceutical molecules across the skin, nasal mucosa and eye through development of proprietary formulations with molecules such as CPE-215Â:registered:. Our first product is TestimÂ:registered:, a gel for testosterone replacement therapy, which is a formulation of our technology with testosterone. Testim is licensed to Auxilium Pharmaceuticals, Inc. (“Auxilium”), which is currently marketing it in the United States, Europe and other countries. We have an additional licensed application with Serenity Pharmaceuticals, Inc. ("Serenity") for Ser-120, a product candidate for the treatment of nocturia. Ser-120, which is currently in multiple Phase 3 trials, utilizes our patented intranasal drug delivery technology. In 2010, Allergan, Inc. assumed our exclusive license agreement with Serenity.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Elan Pharma International Ltd., a subsidiary of Perrigo Co. Plc, is a company headquartered in South San Francisco, CA, that develops, manufactures and distributes pharmaceutical products.

Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to enter for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Manufactures and sells pharmaceuticals

Uneeg Medical A/S is a private company headquartered in Lynge, Denmark. The firm designs and manufactures medical devices.

Functions as an investment holding company

Science & Technology Corp. provides scientific, technical, and engineering services. The firm Specializes in defense chemical and biological research, test and evaluation, range support services, earth and space sciences, polar technologies, aerospace engineering and information systems engineering and support. The company was founded in 1979 and is headquartered in Hampton, VA.

Tianjin Juxing Kanghua Pharmaceutical Technology Co., Ltd., established on 2011-05-12, Business scope includes scientific research and technical service industry;Wholesale and retail trade;Import and export of goods and technology;Wholesale Prepackaged Food(Subject to the Food Circulation Approval Decision).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Longhua Hospital Shanghai University of TCM, a subsidiary of Shanghai University of Traditional Chinese Medicine, is a company headquartered in Shanghai, China. The firm provides hospital services.

Medtronic MiniMed, Inc. manufactures insulin pumps and glucose monitoring systems. Its products include minimed 530g system, smartguard, enlite sensor, minimed revel and infusion sets. The company was founded by Alfred E. Mann in 1979 and is headquartered in Northridge, CA.

Siemens AG is a technology company, which engages in the areas of automation and digitalization in the process and manufacturing industries, infrastructure for buildings and energy systems, mobility solutions for rail transport, and medical technology and digital healthcare services. It operates through the following segments: Digital Industries, Smart Infrastructure, Mobility, Siemens Healthineers, and Siemens Financial Services. The Digital Industries segment offers a product portfolio and system solutions for automation used in discrete and process industries. The Smart Infrastructure segment includes products, systems, solutions, services and software to support a transition from fossil to renewable energy sources. The Mobility segment combines all Siemens businesses in the area of passenger and freight transportation. The Siemens Healthineers segment develops, manufactures, and sells diagnostic and therapeutic products, and services to healthcare providers. The Siemens Financial Services segment focuses on financing solutions for Siemens’ customers as well as other companies in the form of debt and equity investments. The company was founded by Johann Georg Halske and Werner von Siemens on October 12, 1847 and is headquartered in Munich, Germany.

Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA.